hVIVO plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPORF research report →
About the company
hVIVO plc functions as a contract research organization and pharmaceutical service provider, primarily dedicated to evaluating vaccines and antiviral medications. This is achieved through specialized human challenge clinical trials. The company extends its services to a varied clientele, encompassing major pharmaceutical and biotechnology firms, governmental bodies, and public health agencies.
- CEO
- Yamin Mohammed Khan
- IPO
- 2020
- Employees
- 301
- HQ
- London, GB
Price Chart
- Market Cap
- $75.45M
- P/E
- -8.13
- P/S
- 1.02
- P/B
- 1.28
- EV/EBITDA
- -234.48
- Div Yield
- 0.00%
- Gross Margin
- -6.07%
- Op Margin
- -13.13%
- Net Margin
- -12.48%
- ROE
- -14.65%
- ROIC
- -11.14%
- Revenue
- $46.77M · -25.44%
- Net Income
- $-5,992,028.4 · -156.25%
- EPS
- $-0.01 · -155.41%
- Op Income
- $-348,942
- FCF YoY
- -287.88%
- 52W High
- $0.35
- 52W Low
- $0.09
- 50D MA
- $0.09
- 200D MA
- $0.14
- Beta
- 1.72
- Avg Volume
- 492
Get TickerSpark's AI analysis on OPORF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our OPORF coverage
Recent articles, reports, and earnings notes.
No research on OPORF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPORF report →Similar companies
Peers in the same neighborhood.